TICKERNERD
Menu
CHRSCHRSHealthcare · Biotechnology

CHRS Stock Forecast: Coherus Oncology, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$1.33
−0.75% on the day

The 6 Wall Street analysts covering Coherus Oncology, Inc. hold a median 12-month price target of $8.5 — +539.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 52 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$205.5M
Ticker Nerd rank
52 / 100
Median analyst target
$8.50
Analysts covering
6
Revenue$14.3M+39.5% y/y
Operating income−$32.3M
Net income−$20.6M
Free cash flow−$62.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.9%
1M
+9.9%
YTD
−6.3%
1Y
0.0%
From 52W high
−47.0%
From 52W low
+20.9%
$1.10
$2.51
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CHRS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Coherus Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
52 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
74
Size
68
Quality
57
Momentum
50
Accruals
46
Growth
46
Volatility
45
Value
45
Issuance
29

Revisions (74): Analysts have, on balance, been raising their forecasts.

Issuance (29): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CHRS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CHRS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26CHRSHigh $10.00Median $8.50Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
5 Buy1 Hold0 Sell
Low $4.00Median $8.50High $10.00

The green dot is the last close — the median target sits +539.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Aug 2026GuggenheimMaintainsBuy$12 → $10
11 May 2026GuggenheimInitiatesBuy—
22 Jan 2026OppenheimerInitiatesOutperform—
4 Sept 2025Maxim GroupUpgradeBuy—
29 Apr 2025HC Wainwright & Co.ReiteratesBuy—
24 Apr 2025UBSMaintainsNeutral—
11 Mar 2025HC Wainwright & Co.ReiteratesBuy—
23 Jan 2025HC Wainwright & Co.ReiteratesBuy—
22 Jan 2025HC Wainwright & Co.ReiteratesBuy—
5 Dec 2024BairdMaintainsOutperform—
4 Dec 2024HC Wainwright & Co.ReiteratesBuy—
8 Nov 2024BairdMaintainsOutperform—
7 Nov 2024HC Wainwright & Co.ReiteratesBuy—
16 Sept 2024HC Wainwright & Co.ReiteratesBuy—
16 Aug 2024UBSDowngradeNeutral—
5 Aug 2024HC Wainwright & Co.ReiteratesBuy—
1 July 2024BairdMaintainsOutperform—
24 May 2024HC Wainwright & Co.ReiteratesBuy—
13 May 2024Truist SecuritiesMaintainsBuy—
10 May 2024HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CHRS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CHRS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Coherus Oncology, Inc. returned 0.0% against +17.5% for the S&P 500, dividends included.

CHRS vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Oct 25Jan 26Apr 26Jul 26CHRSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CHRS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Coherus Oncology, Inc. (CHRS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.1×

Cheaper than 68% of US stocks

Price / sales
4.0×

Cheaper than 31% of US stocks

Price / book
3.4×

Cheaper than 30% of US stocks

EV / EBITDA
−1.0×

Cheaper than 67% of US stocks

Growth & margins
Revenue growth (YoY)
39.5%

Higher than 83% of US stocks

Earnings growth (YoY)
39.5%

Higher than 71% of US stocks

Gross margin
70.4%

Higher than 83% of US stocks

Operating margin
−226.0%

Higher than 10% of US stocks

Net margin
−259.4%

Higher than 1% of US stocks

Returns & dividend
Return on equity
−178.4%

Higher than 8% of US stocks

Return on assets
−30.5%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Coherus Oncology, Inc. (CHRS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Coherus Oncology, Inc. has a market value of $205.5M and an enterprise value of $154.4M.

  • Revenue in the twelve months to 30 June 2026: $50.9M. The latest quarter grew 39.5% year on year.

  • Net income over the same four quarters: −$132.1M, a −259.4% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.03.

  • Free cash flow in the twelve months to 30 June 2026: −$186.0M.

  • Shares outstanding: 154.5M.

  • Trailing P/E: 3.1×; forward P/E: −2.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Coherus Oncology, Inc. employs 144 people — $354K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

CHRS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CHRSCoherus Oncology, Inc.$205.5M
52
KRROKorro Bio, Inc.$199.2M
29
DTILPrecision BioSciences, Inc.$197.9M
68
ARMPArmata Pharmaceuticals, Inc.$197.1M
71
ANTXAN2 Therapeutics, Inc.$194.4M
72
TNXPTonix Pharmaceuticals Holding Corp.$203.6M
27
NERVMinerva Neurosciences, Inc.$193.3M
32

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Coherus Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CHRS news & analysis

Coherus to Participate in Upcoming Investor Conferences

GlobeNewsWire · 31 Aug 2026neutral

Coherus Oncology, Inc. announced that the company will participate in upcoming investor conferences, as detailed in a press release issued on August 31, 2026. The announcement provides notice of the company's scheduled conference appearances.

Why it matters — CHRS watchers would want to know about the company's planned investor conference appearances to track where and when management will present the company's developments.

Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights

GlobeNewsWire · 17 Aug 2026positive

Coherus Oncology announced a special dividend of contingent value rights (CVRs), distributed pro rata to stockholders of record, entitling holders to receive net proceeds from the sale of its remaining Legacy Biosimilar Assets. The company stated this completes its transformation into a fully integrated, innovative immuno-oncology company.

Why it matters — CHRS shareholders will receive value tied to the sale of the remaining legacy biosimilar assets, and the dividend marks the completion of the company's shift to a fully integrated immuno-oncology focus.

Coherus Oncology, Inc. (CHRS) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Coherus Oncology, Inc. (CHRS) held its Q2 2026 earnings call, and a transcript of the call has been published by Seeking Alpha. The transcript covers the company's second-quarter 2026 earnings discussion.

Why it matters — CHRS watchers would care because the Q2 2026 earnings call transcript provides direct insight into the company's most recent financial results and management commentary.

Coherus Oncology Q2 Earnings Call Highlights

MarketBeat · 6 Aug 2026positive

In its Q2 earnings call, Coherus Oncology reported continued growth for its LOQTORZI treatment and lower operating expenses following the divestiture of its UDENYCA franchise. The company also stated it is approaching several clinical data disclosures in the second half of 2026.

Why it matters — CHRS watchers would care because the upcoming clinical data readouts and reduced cost base could shape the company's near-term outlook and pipeline progress.

Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research · 5 Aug 2026negative

Coherus Oncology (CHRS) reported a second-quarter loss of $0.19 per share, missing the Zacks Consensus Estimate of $0.08. The loss narrowed compared with the $0.34 per share loss reported a year ago.

Why it matters — The quarterly result came in below analyst expectations, a relevant update for CHRS watchers assessing the company's recent earnings performance.

FAQ

Frequently asked questions about CHRS stock

What is the CHRS stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Coherus Oncology, Inc. have a median 12-month price target of $8.5, with estimates ranging from $4 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CHRS stock a buy right now?

Of the 6 analysts covering Coherus Oncology, Inc., 5 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Coherus Oncology, Inc. 52 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CHRS?

As at 12 Sept 2026, Coherus Oncology, Inc. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (74 of 100).

Will CHRS stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +539.1% from the last close, and Ticker Nerd's factor model ranks Coherus Oncology, Inc. 52 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CHRS stock forecast for 2030?

No analyst covering Coherus Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CHRS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $10 over the next 12 months.

How has CHRS stock performed over the past year?

Coherus Oncology, Inc. returned +0.0% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Coherus Oncology, Inc. do?

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies for cancer.

What is the latest news on CHRS?

The most recent item we track (GlobeNewsWire, 31 Aug 2026): "Coherus to Participate in Upcoming Investor Conferences". Coherus Oncology, Inc. announced that the company will participate in upcoming investor conferences, as detailed in a press release issued on August 31, 2026. The announcement provides notice of the company's scheduled conference appearances.

Company

About Coherus Oncology, Inc.

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies for cancer. The company’s current portfolio centers on LOQTORZI, an approved PD-1 inhibitor used in oncology treatment, alongside additional clinical-stage candidates designed to address several solid tumors and tumor types. Coherus Oncology works across research, regulatory development, manufacturing, and commercialization, with an emphasis on combination therapies that may expand the use of its cancer medicines. Its business is concentrated on oncology therapeutics, reflecting a focused role in the cancer drug market and a strategy built around antibody-based and immune-based treatments. Based in Redwood City, California, Coherus Oncology serves as a specialized player in the U.S. biopharmaceutical sector, with its commercial activities and pipeline development aimed at improving treatment options in modern oncology.

CEO Mr. Dennis M. Lanfear · 144 employees · United States · https://www.coherus.com